|
Feb 27
|
First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer
|
|
Feb 14
|
Alphamab doses first subject in trial of JSKN003 for ovarian cancer
|
|
Feb 13
|
High Growth Tech Stocks To Watch In February 2025
|
|
Feb 13
|
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
|
|
Dec 30
|
Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer
|